Show simple item record

dc.contributor.advisorAndrew W. Lo.en_US
dc.contributor.authorKim, Esther Sen_US
dc.contributor.otherTechnology and Policy Program.en_US
dc.date.accessioned2017-09-15T15:28:45Z
dc.date.available2017-09-15T15:28:45Z
dc.date.copyright2017en_US
dc.date.issued2017en_US
dc.identifier.urihttp://hdl.handle.net/1721.1/111315
dc.descriptionThesis: S.M. in Technology and Policy, Massachusetts Institute of Technology, School of Engineering, Institute for Data, Systems, and Society, Technology and Policy Program, 2017.en_US
dc.descriptionCataloged from PDF version of thesis.en_US
dc.descriptionIncludes bibliographical references (pages 119-125).en_US
dc.description.abstractMany obstacles contribute to the uncertainty and risk associated with early drug development, leading to the "valley of death" in which promising drug candidates experience difficulties in reaching the market. These challenges have serious consequences for patient populations facing significant unmet medical needs. In this paper, we highlight three models that offer innovative financing mechanisms or new business models for early stage biopharmaceutical assets. Specifically, we evaluate and profile examples of venture philanthropy and academic-industry partnerships as sources of financial capital for early stage assets. In addition, we identify a "one-disease" business model in biotechnology that can mitigate risk and accelerate the translation of biomedical research into novel therapeutics. The three examples highlight the potential for creative mission-driven models to speed up drug development and provide capital in the earliest, and often riskiest, stages of drug development. These models are collaborative and leverage the expertise of the various stakeholders in the process, including patient advocates, private sector drug developers, and academic researchers.en_US
dc.description.statementofresponsibilityby Esther S. Kim.en_US
dc.format.extent125 pagesen_US
dc.language.isoengen_US
dc.publisherMassachusetts Institute of Technologyen_US
dc.rightsMIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission.en_US
dc.rights.urihttp://dspace.mit.edu/handle/1721.1/7582en_US
dc.subjectInstitute for Data, Systems, and Society.en_US
dc.subjectEngineering Systems Division.en_US
dc.subjectTechnology and Policy Program.en_US
dc.titleNew financing and business models to accelerate the development of novel therapeuticsen_US
dc.typeThesisen_US
dc.description.degreeS.M. in Technology and Policyen_US
dc.contributor.departmentMassachusetts Institute of Technology. Institute for Data, Systems, and Society.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Engineering Systems Division.en_US
dc.contributor.departmentTechnology and Policy Program.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Engineering Systems Division
dc.contributor.departmentMassachusetts Institute of Technology. Institute for Data, Systems, and Society
dc.contributor.departmentMassachusetts Institute of Technology. Technology and Policy Program
dc.identifier.oclc1003289786en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record